Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 108, Issue 8, 2016, Pages

  Kuczynski, Elizabeth A ^a   Yin, Melissa ^b   Bar Zion, Avinoam ^a   Lee, Christina R ^b   Butz, Henriett ^d   Man, Shan ^b   Daley, Frances ^e   Vermeulen, Peter B ^e,f   Yousef, George M ^d   Foster, F Stuart ^a,b   Reynolds, Andrew R ^c,e,f   Kerbel, Robert S ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f GZA Hospitals St Augustinus   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; STAT3 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR; VIMENTIN; WNT PROTEIN; ACTA2 PROTEIN, HUMAN; ACTIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CD34 ANTIGEN; CONTRAST MEDIUM; HOMEODOMAIN PROTEIN; NICOTINAMIDE; OSTEOPONTIN; REPRESSOR PROTEIN; SPP1 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN; ZEB2 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VOLUME; CELL PROLIFERATION; CONTROLLED STUDY; INTRACELLULAR SIGNALING; LIVER BLOOD VESSEL; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER METASTASIS; LIVER PARENCHYMA; LIVER SIZE; LIVER STRUCTURE; LYMPH VESSEL METASTASIS; MALE; MICROVASCULATURE; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION; VESSEL CO-OPTION; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BLOOD VESSEL; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG RESISTANCE; ECHOGRAPHY; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HUMAN; LIVER; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SCID MOUSE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR INVASION; VASCULARIZATION;

ACTINS; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; OSTEOPONTIN; PHENYLUREA COMPOUNDS; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; ULTRASONOGRAPHY; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIMENTIN; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84992401796     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw030     Document Type: Article

References (43)

1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-390.
2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1):25-34.
3. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-3140.
4. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer. 2012; 12(10):699-709.
5. Vasudev N, Reynolds A. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471-494.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8(4):299-309.
7. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell. 2011; 19(4):512-526.
8. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014; 20(8): 2072-2079.
9. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. Am J Roentgenol. 2010; 194(1):157-165.
10. Vasudev NS, Goh V, Juttla JK, et al. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Br J Cancer. 2013; 109(5):1230-1242.
11. Nowosielski M, Wiestler B, Goebel G, et al. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology. 2014; 82(19):1684-1692.
12. Donnem T, Hu J, Ferguson M, et al. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? Cancer Med. 2013; 2(4):427-436.
13. Vermeulen PB, Colpaert C, Salgado R, et al. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia J Pathol. 2001; 195(3):336-342.
14. Pezzella F, Di Bacco A, Andreola S, Nicholson AG, Pastorino U, Harris AL. Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer. 1996; 32(14):2494-2500.
15. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997; 151(5):1417-1423.
16. Naresh KN, Nerurkar AY, Borges AM. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology. 2001; 38(5):466-470.
17. Jeong HS, Jones D, Liao S, et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases J Natl Cancer Inst. 2015; 107(9): djv155.
18. Fumagalli E, Coco P, Morosi C, Bertulli R, Casali PG, et al. Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy. J Clin Oncol. 2010; 28(Suppl);e20519.
19. Nozawa M, Yamamoto Y, Minami T, et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int. 2012; 110(6 Pt B):E228-E234.
20. Albiges L, Choueiri T, Escudier B, et al. A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. Eur Urol. 2015; 67(1):100-110.
21. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol. 2013; 10(10):571-587.
22. Tang TC, Man S, Xu P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010; 12(11):928-940.
23. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010; 9(6):1525-1535.
24. Zhang L, Bhasin M, Schor-Bardach R, et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011; 6(4):e19144.
25. Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010; 12(3):264-274.
26. Riechelmann RP, Chin S, Wang L, et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. AmJ Clin Oncol. 2008; 31(2):182-187.
27. Ruck P, Xiao JC, Kaiserling E. Immunoreactivity of sinusoids in hepatoblastoma: an immunohistochemical study using lectin UEA-1 and antibodies against endothelium-associated antigens, including CD34. Histopathology. 1995; 26(5):451-455.
28. Foster FS, Burns PN, Simpson DH, Wilson SR, Christopher DA, Goertz DE. Ultrasound for the visualization and quantification of tumor microcirculation. Cancer Metastasis Rev. 2000; 19(1-2):131-138.
29. Nakashima T, Kojiro M, Kawano Y, et al. Histologic growth pattern of hepatocellular carcinoma: relationship to orcein (hepatitis B surface antigen)-positive cells in cancer tissue. Hum Pathol. 1982; 13(6):563-568.
30. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol. 2012; 25(10):1315-1325.
31. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3):220-231.
32. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-239.
33. van Malenstein H, Dekervel J, Verslype C, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2013; 329(1):74-83.
34. Blagoev K, Wilkerson J, Stein W, Motzer R, Bates S, Fojo A. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma. Cell Rep. 2013; 3(2):277-281.
35. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005; 65(14):5996-6000.
36. Chui MH Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step. Int J Cancer. 2013; 132(7):1487-1495.
37. Friedl P, Locker J, Sahai E, Segall JE. Classifying collective cancer cell invasion. Nat Cell Biol. 2012; 14(8):777-783.
38. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002; 62(24):7203-7206.
39. Chen R, Xia Y, Xue T, Ye S. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression. Mol Biol Rep. 2011; 38(6):3671-3677.
40. Wick W, Wick A, Weiler M, Weller M. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Curr Neurol Neurosci Rep. 2011; 11(3):305-312.
41. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010; 12(3):233-242.
42. Sugihara S, Kojiro M, Nakashima T. Ultrastructural study of hepatocellular carcinoma with replacing growth pattern. Acta Pathol Jpn. 1985; 35(3): 549-559.
43. Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential pro-invasive or metastatic effects of preclinical antiangiogenic therapy are prevented by concurrent chemotherapy. Clin Cancer Res. 2015; 21(24):5488-5498.